For UK MedTech companies
Your device works. The finance team still won't approve it.
NHS procurement now demands a health economic case alongside clinical evidence. Without a credible cost-effectiveness model, clinical merit alone will not clear the business case, and each failed attempt costs a year or more and a substantial sum in sales resource.
Two minutes. Solva follows up with specific health economics options.
NICE's 2024 MedTech evaluation guidance requires all devices seeking NHS adoption to provide a budget impact analysis. 60% of MedTech submissions are delayed or rejected at this stage due to insufficient economic evidence. (NICE, 2024)
Frequently asked questions
Why does this problem persist?
NHS procurement increasingly requires a health economic argument alongside clinical evidence. MedTech companies often have strong clinical data but lack a cost-effectiveness model, a cost-per-procedure comparison, or a budget impact analysis that finance directors and commissioners can use to justify the purchase.
What is the cost of leaving it unaddressed?
Without a health economic argument, your device will not pass NHS procurement scrutiny regardless of clinical merit. Each failed procurement attempt costs 12–18 months and typically £50,000–£150,000 in sales resource. (NICE, 2024)
This is exactly what I do with UK private practices. Answer the few questions above and I'll come back personally with where to start. Paul.